Rankings / Comparisons

Caffeine vs L-theanine

The famous caffeine+theanine stack — what each does alone, and why the combination is studied separately.

Score comparison

Caffeine has the higher descriptive composite (A+, 8.4/10) compared with L-theanine (B+, 7.1/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.

Caffeine

A+ 8.4/10

Evidence
Strong (acute alertness, attention, reaction time) (8/10)
Benefit
High (8/10)
Risk
Low (ordinary dietary use; dependence, sleep disruption, anxiety in sensitive users); Very High for pure/bulk powder misuse (9/10 safety)
Legality
OTC / dietary
Dose / route context
40-400 mg/day; tolerability protocols for caffeine-naive adults commonly begin at 50-100 mg
Class
Supplement
Last reviewed
Aug 13, 2026

Read Off Label grades Caffeine as A+ (8.4/10) based on strong evidence, high benefit magnitude, and a low-risk safety profile.

Most widely used psychoactive drug.

Studied, labeled, or reported-use context: 40-400 mg/day; tolerability protocols for caffeine-naive adults commonly begin at 50-100 mg — OTC / dietary; not individualized guidance.

What it is

Most widely used psychoactive drug. FDA and EFSA both treat up to ~400 mg/day as generally safe for most healthy non-pregnant adults, but timing is crucial: the ~5-hour half-life can disrupt sleep if taken after mid-afternoon. Tolerance builds rapidly and dose escalation is common. Pure or highly concentrated caffeine powders/liquids are a separate hazard because small measuring errors can be toxic or fatal. Caffeine and L-theanine have also been studied in combination for acute attention outcomes.

Mechanism

Non-selective adenosine A1/A2A receptor antagonist; blocks tonic inhibition of wake-promoting neurons; indirectly elevates dopamine/norepinephrine; cAMP elevation via PDE inhibition at high doses

Full Caffeine review →

L-theanine

B+ 7.1/10

Evidence
Moderate (acute attention -- 2026 31-RCT meta-analysis confirms as monotherapy; also combined with caffeine) (6/10)
Benefit
Med (5/10)
Risk
Low (9/10 safety)
Legality
OTC
Dose / route context
100-400 mg/day; commonly 100-200 mg paired with caffeine
Class
Supplement
Last reviewed
Jul 30, 2026

Read Off Label grades L-theanine as B+ (7.1/10) based on moderate evidence, med benefit magnitude, and a low-risk safety profile.

Combination with caffeine is the most evidence-backed nootropic stack — Camfield 2014 meta-analysis showed moderate improvements in attention switching/accuracy in first 2 hours post-dose.

Studied, labeled, or reported-use context: 100-400 mg/day; commonly 100-200 mg paired with caffeine — OTC; not individualized guidance.

What it is

Combination with caffeine is the most evidence-backed nootropic stack — Camfield 2014 meta-analysis showed moderate improvements in attention switching/accuracy in first 2 hours post-dose. Ratio typically 2:1 theanine:caffeine. A 2026 systematic review/meta-analysis (31 RCTs, n=1,168; Molecular Psychiatry) found a single 200 mg dose significantly improved choice reaction time (SMD 0.51) as monotherapy -- the first large pooled synthesis of L-theanine alone, not just the caffeine stack. Stress reduction was modest and largely driven by high-risk-of-bias studies; no effect on fatigue; a preliminary antidepressant signal (SMD 0.69) needs confirmation in clinical populations.

Mechanism

Non-proteinogenic amino acid from tea; crosses BBB; increases alpha brain waves; mild GABA agonism; glutamate receptor modulation; calming without sedation

Full L-theanine review →

Common questions

How do the evidence profiles of Caffeine and L-theanine compare?
Caffeine has the higher descriptive composite (A+, 8.4/10) compared with L-theanine (B+, 7.1/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.
What's the difference between Caffeine and L-theanine?
The famous caffeine+theanine stack — what each does alone, and why the combination is studied separately.
Can you take Caffeine and L-theanine together?
The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.

This is an independent synthesis of published research by a non-clinician. The comparison reports composite and axis-level differences without selecting an intervention for the reader. Relevance depends on indication, population, dose, duration, and other context. See the full disclaimer and methodology.